X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Aurobindo Pharma Fact Sheet, Aurobindo Pharma Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Aurobindo Pharma Fact Sheet   (AUBD)

Here is the latest financial fact sheet of Aurobindo Pharma. For more details, see the Aurobindo Pharma quarterly results and Aurobindo Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.

AUROBINDO PHARMA Price History

Price Rs 709.5
Mkt Cap Rs m 415,177
Vol '000 138.7
P/E X 18.1
P/CF X 15.2
EPS (TTM) Rs 39.2
% ch % 2.0
No. of shares m 585.17
% ch week % -0.5
% ch 1-mth % -5.5
% ch 12-mth % -3.0
52 week H/L Rs 809.0/504.0
(As on Nov 24, 2017 02:37:00 PM)
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

AUROBINDO PHARMA Financials

No. of Mths
Year Ending
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
12
Mar-17
*
5-Yr Chart
Click to enlarge
AUROBINDO PHARMA EQUITY SHARE DATA
High Rs2055451,2801,541895 
Low Rs100139509582622 
Sales per share (Unadj.) Rs201.1277.9415.1235.8254.6 
Earnings per share (Unadj.) Rs10.140.254.034.639.3 
Diluted earnings per shareRs5.020.026.934.639.3 
Cash flow per share (Unadj.) Rs18.651.065.441.346.6 
Dividends per share (Unadj.) Rs1.503.004.502.502.50 
Adj. dividends per shareRs0.751.492.252.502.50 
Dividend yield (eoy) %1.00.90.50.20.3 
Book value per share (Unadj.) Rs89.5128.7184.5124.5160.0 
Adj. book value per shareRs44.564.192.0124.5160.2 
Shares outstanding (eoy) m291.21291.46291.98585.17585.88 
Bonus/Rights/Conversions  ---PREFESOP 
Price / Sales ratio x0.81.22.24.53.0 
Avg P/E ratio x15.18.516.630.719.3 
P/CF ratio (eoy) x8.26.713.725.716.3 
Price / Book Value ratio x1.72.74.88.54.7 
Dividend payout %14.97.58.37.26.4 
Avg Mkt Cap Rs m44,35199,577261,147621,041444,390 
No. of employees `0008.89.511.613.314.0 
Total wages/salary Rs m6,6338,02413,02315,42617,678 
Avg. sales/employee Rs Th6,653.88,526.110,469.510,384.310,667.8 
Avg. wages/employee Rs Th753.8844.71,124.91,160.91,264.3 
Avg. net profit/employee Rs Th333.91,234.61,361.11,522.91,645.8 
AUROBINDO PHARMA INCOME DATA
Net Sales Rs m58,55380,998121,205137,986149,157 
Other income Rs m2852169672,0381,159 
Total revenues Rs m58,83981,214122,172140,024150,316 
Gross profit Rs m8,61021,33725,63631,88234,343 
Depreciation Rs m2,4873,1253,3263,9244,276 
Interest Rs m2,6663,1021,5992,568667 
Profit before tax Rs m3,74115,32521,67927,42930,558 
Minority Interest Rs m2538451550 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m8273,6355,9667,2077,597 
Profit after tax Rs m2,93911,72915,75820,23623,012 
Gross profit margin %14.726.321.223.123.0 
Effective tax rate %22.123.727.526.324.9 
Net profit margin %5.014.513.014.715.4 
AUROBINDO PHARMA BALANCE SHEET DATA
Current assets Rs m41,36856,31283,794102,94492,062 
Current liabilities Rs m34,30842,20060,81478,40266,223 
Net working cap to sales %12.117.419.017.817.3 
Current ratio x1.21.31.41.31.4 
Inventory Days Days120107108107106 
Debtors Days Days10011910712268 
Net fixed assets Rs m28,57427,36639,21850,27862,919 
Share capital Rs m291292292585586 
"Free" reserves Rs m25,06235,80253,56572,28893,133 
Net worth Rs m26,05837,50253,85772,87393,719 
Long term debt Rs m11,48312,79413,1117,4281,814 
Total assets Rs m72,77894,898128,124159,202162,494 
Interest coverage x2.45.914.611.746.8 
Debt to equity ratio x0.40.30.20.10 
Sales to assets ratio x0.80.90.90.90.9 
Return on assets %7.715.613.514.314.6 
Return on equity %11.331.329.327.824.6 
Return on capital %17.136.734.837.432.7 
Exports to sales %66.165.851.651.40 
Imports to sales %31.226.719.219.00 
Exports (fob) Rs m38,71053,26962,51470,9270 
Imports (cif) Rs m18,27921,60723,27226,1930 
Fx inflow Rs m39,05653,42062,61371,01575,838 
Fx outflow Rs m19,44623,25125,32928,79930,224 
Net fx Rs m19,61030,16937,28442,21645,613 
AUROBINDO PHARMA CASH FLOW
From Operations Rs m 2,749 6,463 12,368 14,198 32,786 
From Investments Rs m -2,463 -8,187 -13,980 -14,452 -17,870 
From Financial Activity Rs m 1,081 1,176 932 3,654 -19,153 
Net Cashflow Rs m 1,366 -548 -680 3,397 -4,239 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 54.1%
Foreign collaborators 0.0%
Indian inst/Mut Fund 8.0%
FIIs 27.7%
ADR/GDR 0.0%
Free float 10.2%
Shareholders 69,601
Pledged promoter(s) holding 8.6%
 

Company Information

REGD OFF Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038
E-MAIL cs@aurobindo.com WEB www.aurobindo.com
TELEPHONE (040) 6672 5333 FAX (040) 2374 1080
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Karvy Computershare, 17-24, Vithalrao Nagar, Madhapur, Hyderabad-81
AUDITOR S. R. Batliboi & Assoc.
CHM: K. Ragunathan COMP SEC: A. Mohan Rami Reddy YEAR OF INC: 1986 BSE CODE: 524804 FV (Rs): 1 DIV YIELD (%): 0.4

More Pharmaceuticals Company Fact Sheets:   SANOFI INDIA  ORCHID PHARMA LTD  GSK PHARMA  TTK HEALTHCARE  PFIZER  

Compare AUROBINDO PHARMA With:   SANOFI INDIA  ORCHID PHARMA LTD  GSK PHARMA  TTK HEALTHCARE  PFIZER  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Green; IT Stocks Top Gainers(01:30 pm)

After opening the day marginally higher, share markets in India continued the momentum and are presently trading in green.

Views on news

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Your Last Chance to Trade ONLY the Best Stocks(Daily Profit Hunter)

Nov 11, 2017

Techno-Funda opportunities are knocking on your door. Are you ready to receive them?

Of Falling Real Estate Prices, Dr Arvind Panagariya and the Art of Continuing to Suck Up(Vivek Kaul's Diary)

Nov 13, 2017

Dr Panagariya claims real estate prices have fallen 25 per cent post demonetisation; the official data doesn't show anything like that.

Why I am the Biggest India Equity Bull on Planet Earth!(The Honest Truth)

Nov 16, 2017

If you have a dream, dream big...about the level of BSE 30 index in 2050!

When the Sherlock Holmes in Me Follows Super Investors...(The 5 Minute Wrapup)

Nov 11, 2017

This Super Investor has knack of spotting megatrends in India.

The Day Warren Buffett Lost All His Money(Smart Contrarian)

Nov 15, 2017

Buffett is still using the lessons he learnt that fateful day.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS